Creating A New Dosage Form From An Approved Drug For A New Rare Disease Indication

Re-evaluating approved therapeutics for new therapeutic indications requires overcoming significant formulation and regulatory hurdles under compressed timeframes. Successfully reformulating a BCS Class II molecule into a lower-dose hard gelatin capsule for a rare genetic blood vessel disorder demonstrates how strategic technical agility can overcome initial regulatory setbacks. Key strategies include conducting thorough early gap analyses, prioritizing simple and stable formulations utilizing readily available excipients, and leveraging deep Chemistry and Manufacturing Controls (CMC) expertise.

Furthermore, executing parallel development and analytical workflows ensures rapid investigational new drug submissions without sacrificing rigorous quality standards. Embracing comprehensive risk management and collaborative multidisciplinary teamwork enables developers to transition swiftly from initial clinical trial support to large-scale commercial manufacturing.

Explore the full case study to uncover the complete eight-step framework for accelerating your next drug repurposing program.